Melanotan-2
MT-II, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Melanotan-2 (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective melanocortin receptor agonist. Originally developed for skin pigmentation research, it has also been investigated for erectile dysfunction. NOT FDA approved and carries significant safety warnings from health agencies worldwide due to serious adverse effects including potential melanoma risk.
Complete Research Database
Phase I Safety Study
View StudyEvaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
PRIMARY RESULTS
Dose-dependent skin pigmentation and sexual effects at 0.01-0.03 mg/kg with mild nausea
KEY FINDINGS
- •Spontaneous penile erections 1-5 hours post-dose
- •Visible skin pigmentation observed
- •Mild nausea at most dose levels
- •Grade II somnolence at highest dose (0.03 mg/kg)
Erectile Dysfunction Study
View StudySynthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction
PRIMARY RESULTS
80% response rate with 38-minute mean duration of >80% penile rigidity vs 3 minutes placebo
KEY FINDINGS
- •Statistically significant erection improvement (p=0.0045)
- •8 out of 10 men achieved functional erections
- •No requirement for sexual stimulation
- •Side effects included nausea and yawning
Extended ED Research
View StudyMelanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II
PRIMARY RESULTS
17/20 men achieved erections with 41-minute average duration and increased sexual desire
KEY FINDINGS
- •85% overall response rate (17/20 participants)
- •Sexual desire increased after 68% of doses
- •Mean rigidity duration of 41 minutes
- •Nausea reported as primary side effect
Toxicity Case Report
View StudyMelanotan II injection resulting in systemic toxicity and rhabdomyolysis
PRIMARY RESULTS
Severe systemic toxicity including rhabdomyolysis and renal dysfunction at 6mg dose
KEY FINDINGS
- •Dose was 6x higher than research protocols
- •Rhabdomyolysis with elevated creatine kinase
- •Acute renal dysfunction requiring hospitalization
- •Demonstrates narrow therapeutic window
Medical Disclaimer
CRITICAL WARNING: Melanotan-2 is NOT approved by the FDA or any major regulatory agency for human use. Health authorities worldwide have issued warnings against its use due to serious safety risks including potential melanoma, priapism, rhabdomyolysis, and systemic toxicity. This information is for educational and research purposes only. Any use requires medical supervision and carries significant legal and health risks. Consult healthcare providers for approved alternatives.